Ụlọ Ọrụ Na-ahụ Maka N'Ịntanet, Canada Nweta Ụlọ, European Delivery Delivery

Mitoxantrone HCL ntụ ntụ

Rating:
5.00 si 5 dabere na 1 ahịa fim
SKU: 70476-82-3. Category:

AASraw nwere njikọ na mmepụta site na gram ka usoro nchịkọta nke Mitoxantrone HCL powder (70476-82-3), n'okpuru usoro CGMP na usoro nchịkwa mma.

Mitoxantrone hydrochloride ntụ ntụ bụ ọgwụ cancer na-egbochi uto ma gbasaa mkpụrụ ndụ cancer n'ime ahụ. A na-eji mmanụ aṅụ Mitoxantrone HCL eme ihe banyere ọrịa kansa prostate na ụdị ụfọdụ nke leukemia. A na-ejikwa mmanụ aṅụ Mitoxantrone HCL na-emeso ihe mgbaàmà nke ịlọghachite ọtụtụ sclerosis. Nri a agaghị agwọ ọtụtụ sclerosis.

Product Description

Mitoxantrone hydrochloride ntụ ntụ video


Mitoxantrone hydrochloride ntụ ntụ isi agwa

aha: Mitoxantrone hydrochloride ntụ ntụ
CAS: 70476-82-3
Molekụla Formula: C22H30Cl2N4O6
Ọbara arọ: 517.4
Melt Point: 160-162 ° C
Nchekwa Nche: friji
agba: White ma ọ bụ na-acha ọcha Crystalline ntụ ntụ


Mitoxantrone hydrochloride ntụ ntụ na ojiji

aha

Aha aha: Novantrone
Chemical Name: 1,4-dihydroxy-5,8-bis [[2- [2-hydroxyethyl] amino] ethyl] amino] 9,10-anthracenedione dihydrochloride

Mitoxantrone hydrochloride ntụ ntụ eji

Nnukwu ọrịa kansa ọbara myeloid

Ihe dị iche iche nke usoro ọgwụgwọ chemotherapy maka ntinye ntinye aka na myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL). AML gụnyere nnukwu promyelocytic, monocytic, myelomonocytic, megakaryoblastic, na erythroid leukemias.

E jiri ya na ndị ọzọ antineoplastic na-eme ka usoro ọgwụgwọ na-agbakwasị ụkwụ na-esote ntinye zuru ezu.

Ọwara Ọrịa
Ejiri ya dị ka usoro ọzọ maka mmalite ọgwụgwọ nke dị elu, ihe mgbaàmà (nke bụ, mgbu) hormone-cancer-prostate refractory (dịka prednisone). Nhọrọ nke usoro ọgwụgwọ maka hormone-ọrịa cancer prostate na-agbanwe agbanwe bụ docetaxel jikọtara na prednisone.

Ọtụtụ Sclerosis (MS)
Ọgwụgwọ nke abụọ (na-adịghị ala ala) na-aga n'ihu, na-aga n'ihu, ma ọ bụ na-arịwanye elu na-alaghachi-na-enye MS. Eji ya iji belata ọrịa nkwarụ na / ma ọ bụ ugboro ole nlọghachi.

Ejiri ọrịa ndị na-esonụ na-amụ ọrịa: N'iji nwayọọ nwayọọ na-arịwanye elu na nkwarụ na ma ọ bụ na-enweghị nlọghachị nke ahụike (nke abụọ na-aga n'ihu na nke na-aga n'ihu) na nlọghachị ahụ na-eme ka enwekwuo nkwarụ, ịnyeghachi ọrịa).

Ekwadoghị ka o jiri ya na ndị ọrịa nwere MS.

Agaghị eji ya maka ọgwụgwọ MS na ndị nwere ọrịa LVEF <50% (seeMyocardial Toxicity in Warning Boxed). A naghị atụ aro ka a jiri ya mee ihe na ndị na-arịa ọrịa na-agwọ ọrịa ahụ (lee Mmetụta Mgbochi n'okpuru Mgbochi) ma ọ bụ ndị nwere neutrophil ọnụ <1500 / mm3.

Lymphoma Na-abụghị Hodgkin
Eji ya mee ihe dịka akụkụ nke usoro ọgwụgwọ chemotherapy maka ọgwụgwọ lymphoma nke na-abụghị nke Hodgkin †.

Kedu ihe bụ usoro mitoxantrone hydrochloride ntụ ntụ

Dị ka Mitoxantrone hydrochloride ntụ ntụ; nyocha e gosipụtara na minoxantrone HCL ntụ ntụ.

ndị okenye
Nnukwu ọrịa kansa ọbara myeloid
Ngwọta Ngwọta
IV
12 mg / m2 kwa ụbọchị na ụbọchị 1-3 na 100 mg / m2 cytarabine kwa ụbọchị (dịka mmụgharị IV n'oge 24) n'ụbọchị 1-7.

Ọ bụrụ na nzaghachi antileukemic na nke mbụ mbu ọmụmụ ezughị ezu, enwere ike inye akwụkwọ nkuzi nke abụọ nke 2 ụbọchị mpoxantrone HCL powder (12 mg / m2 kwa ụbọchị) na 5 ụbọchị nke cytarabine (100 mg / m2 kwa ụbọchị).

Ọ bụrụ na a na-ahụ nsí na-adịghị njọ ma ọ bụ na-eyi egwu egwu na-adị ndụ na mbụ n'oge mbụ a na-emepụta ihe, gbochie ntinye nke mbempe akwụkwọ ruo mgbe mgbubibi na-edozi.

Ọgwụgwọ Ndozi
IV
12 mg / m2 kwa ụbọchị na 1 na 2 na 100 mg / m2 cytarabine kwa ụbọchị (dịka mmụgharị IV n'oge 24) n'ụbọchị 1-5. Na-eduzi usoro nkwekọrịta mbụ dịka izu 6 mgbe nkuzi mmechi ikpeazụ; nyezie usoro nhazi nke abụọ n'ozuzu izu 4 mgbe ọ gwụchara.

Ọwara Ọrịa
IV
12-14 mg / m2 otu ugboro n'ụbọchị 21 niile; nye ya ka ọ bụrụ ọgwụgwọ corticosteroid (dịka, prednisone 5 mg ugboro abụọ kwa ụbọchị, hydrocortisone 40 mg kwa ụbọchị). Ụfọdụ ndị dọkịta na-atụ aro ịhapụ minoxantrone HCL ntụ ntụ (na n'ihu ọgwụgwọ corticosteroid naanị) na ndị ọrịa ka na-azaghachi mgbe mpoxantrone HCL powder dose nke 140 mg / m2 n'ihi ihe ize ndụ nke ọrịa obi.

multiple Sclerosis
IV
12 mg / m2 otu ugboro n'ọnwa 3.

Na-akọwa Limits
ndị okenye
multiple Sclerosis
IV
Mkpụrụ ndụ zuru oke dị ogologo: 140 mg / m2.

Mkpa Ndị Pụrụ Iche
Mmetụta Ahụhụ Na-adịghị
Ịkwụsị nkwụsị; Otú ọ dị, enwere ike ịhazigharị usoro ọgwụgwọ, ọ bụghị usoro ọgwụgwọ edozi. (Lee Mmetụta Na-akpata Hepatic n'okpuru Nkwado.)

Mmetụta Mberede
Mbelata ọgwụgwọ anaghị achọ.

Ịdọ aka ná ntị

Ahụmahụ nke nlekọta nyocha

Na-elekọta naanị n'okpuru nlekọta nke ndị dọkịta ruru eru nwere ahụmahụ na ọgwụgwọ cytotoxic.

Ntuziaka nchịkwa
Na-eduzi nwayọọ nwayọọ n'ime ihe ngwọta IV infusion na-agba ọsọ ọsọ. Emela IM, sub-Q, intra-arterial, ma ọ bụ intrahection ogwu.

Nnukwu anụ ahụ bụ necrosis ma ọ bụrụ na mmepụta ahụ emee. (Lee mmetụta ndị dị na mpaghara n'okpuru ngbochi.)

O siri ike na mgbe ụfọdụ irreversible neurotoxicity kọrọ na-eso intrathecal ochichi. (Lee Neurotoxicity n'okpuru Nkwado.)

Myelosuppression
Myelosuppression siri ike nwere ike ime. Akwụsịkarị iji ndị ọrịa nwere akara neutrophil na-agụ <1500 / mm3, ma e wezụga maka ọgwụgwọ nke ọrịa ọbara ọbara ọbara (myelogenous, nonlymphocytic). Nyochaa ihe omimi nke oma. (Lee Mmetụta Hematologic n'okpuru Nkwado.)

Ọrịa myocardial
Omume cardiotoxicity ma nwee ike igbu CHF n'oge ma ọ bụ ọnwa ruo ọtụtụ afọ; enwekwu ihe ize ndụ na ụba na-arịwanye elu.

Ihe ndị dị ize ndụ (akụkọ ihe mere eme nke ọrịa obi ma ọ bụ nke dị ugbu a, ọgwụ ma ọ bụ nkwekọrịta na-aga n'ihu na mpaghara ọgwụ / ọrịa, usoro ọgwụgwọ na ọgwụ ndị ọzọ na anthracenediones, ma ọ bụ iji ọgwụ ndị ọzọ na-agwọ ọrịa) nwere ike ime ka ọrịa cardiotoxicity. Otú ọ dị, ọnyá pụrụ ime n'agbanyeghị ma ihe gbasara ihe ize ndụ nke obi dị. (Lee Cardiotoxicity n'okpuru Ịma Aka.)

Echiche nke CHF na-emepe emepe na ndị ọrịa cancer na-eme atụmatụ na ha bụ 2.6% na nghazi agwakọta nke 140 mg / m2.

Tupu ịmalite ịgwọ ọrịa, nyochaa ndị ọrịa niile maka ihe ịrịba ama na mgbaàmà obi obi site n'akụkọ ihe mere eme na nyocha anụ ahụ ma chọpụta mkpụrụ ndụ ventricular ejection fraction (LVEF) site na echocardiogram ma ọ bụ multigated radionuclide angiography (MUGA).

Ejila otutu sclerosis na-agwọ ọrịa ma ọ bụrụ na LVEF bụ <50%.

N'ọrịa ndị nwere ọtụtụ sclerosis, nyochaa LVEF site na echocardiogram ma ọ bụ MUGA tupu ngwakọ ọ bụla; adighi edozi onu ozo ma oburu na LVEF adighi adi na <50% ma ọ bụrụ na Mbelata Mbelata dị na LVEF pụtara.

Ndị ọrịa nwere ọrịa sclerosis dị iche iche ekwesịghị ịnata ọgwụ mmụkọta> 140 mg / m2.

Ọrịa kansa ọbara mịkalị nke abụọ (AML)
AML nke abụọ na-akọwara ndị ọrịa mesoro mpoxantrone HCL ntụ ntụ; ihe ize ndụ nke leukemias nke abụọ na-emewanye mgbe anjikọtara anthracycline na antineoplastics DNA nke na-emebi emebi, mgbe ọ na-ekpughechasị ọgwụ ndị na-agwọ ọrịa cytotoxic, ma ọ bụ mgbe usoro anthracycline arịwanye elu (Lee Carcinogenicity under Cundions.)

Mitoxantrone hydrochloride Flux Powder

Min iji 10grams.
Ajuju ajuju nke di n'ogo (N'ime 1kg) nwere ike iziputa na 12 awa mgbe ugwo.
Enwere ike iziga usoro ka ukwuu na 3 ụbọchị ọrụ mgbe ịkwụ ụgwọ.

Mitoxantrone hydrochloride ntụ ntụ Marketing

A ga-enye ha n'ọdịnihu na-abịa.

Mitoxantrone HCL ntụ ntụ nwere mmetụta ọ bụla

Ihe kpatara nsogbu nke mitoxantrone gụnyere: ọrịa, ọrịa mgbagwoju anya, ọrịa urinary tract, ọrịa fungal, ọrịa akpụkpọ anụ, ọnyá, alopecia, amerrhea, ọrịa arrhythmia obi, constipation, afọ ọsịsa, ọrịa ecg, ọbara ọgbụgba, ọnụọgụ gamma-glutamyl transferase, Leukopenia, ọrịa ịmịrịa, ọgbụgbọ, stomatitis, ọrịa mịnwụ, nkwonkwo ụbụrụ, aphthous stomatitis, asthenia, ihe ọkụ ọkụ na-egbu ọkụ, trak, hemoglobin na-ebelata, ọnụ ọgụgụ ọbara ọbara ọcha, dyspnea, edema, nsogbu mgbu, ike ọgwụgwụ, ọkụ, hematuria, hyperglycemia, hypocalcemia, hypokalemia, glucose dịkwuo, lymphocytopenia, mucositis, pharyngitis, rhinitis, mgbu afo, thrombocytopenia, vomiting, uru uru, ihe na-adabaghị adaba na neutrophil, anorexia, malaise, na nailbedchanges. Mmetụta ndị ọzọ na - agụnye: ịrịa oyi, nkwonkwo akwara, njigide, ịrịa ọrịa, anaemia, mgbu azụ, granulocytopenia, isi ọwụwa, sinusitis, nchekasị, arthralgia, conjunctivitis, ịda mbà n'obi, dyspepsia, ọbara ọbara ọbara nke nwoke, ọbara ọgbụgba, ọbara mgbatị, hyponatremia, alanine aminotransferase, ọnụọgụ dịka aspartate aminotransferase, ọrịa nke ọrịa obi, myalgia, mgbu, petechia, proteinuria, ọnya, bruise, mkpu, diaphoresis, na ecchymoses. Lee n'okpuru maka ndepụta zuru oke nke mmetụta ọjọọ.


Esi zụta Mitoxantrone hydrochloride ntụ ntụ si AASraw

1.To kpọtụrụ anyị site na email anyị usoro nyocha, ma ọ bụ skypeonye na-ahụ maka ndị ahịa (CSR).
2.To nye anyị ọnụọgụgụ na adreesị gị.
3.OUR CSR ga-enye gị nkọwa, okwu nkwụ ụgwọ, nọmba nchịkọta, ụzọ nnyefe na ụbọchị mbata echere (ETA).
4.Bayment done and the goods will be sent out na 12 awa (N'ihi na iwu n'ime 10kg).
5.Goods natara ma kwuo ihe.


=

COA

COA 70476-82-3Mitoxantrone HCL ntụ ntụ AASRAW

HNMR

Anyị bụ Mitoxantrone hydrochloride uzuzu, Mitoxantrone HCL uzuzu maka ire ere, Mwne Mantxantrone HCL ngwurcha sulu (70476-82-3) hplc ma98% | AASraw

Ezi ntụziaka

Mitoxantrone hydrochloride Ntụ ntụ ntụ ntụ ntụ

Ịjụ ajụjụ maka ndị na - anọchite anya anyị (CSR) maka nkọwa, maka amaokwu gị.

Ntughari & akwukwo akwukwo

1 nyochaa maka Mitoxantrone HCL ntụ ntụ

  1. gosiri 5 si 5

    Aasraw -

    Mitoxantrone HCL ntụ ntụ bụ ọgụgụ isi

Tinye a nyochaa

Na adreesị email gị agaghị bipụtara. Chọrọ ubi na- *